Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
212Pb-LNC1011M
- Development stage
- Preclinical
- Lead developer
- LNC Pharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
212Pb-LNC1011M is a targeted alpha-therapy (TAT) radiopharmaceutical developed by LNC Pharma for the treatment of prostate cancer. The drug candidate consists of a small-molecule ligand, LNC1011M, designed to bind with high affinity to the prostate-specific membrane antigen (PSMA), which is frequently overexpressed in prostate cancer cells. This ligand is conjugated to Lead-212 (212Pb), a radioisotope that serves as a source of alpha particles. Upon binding to PSMA and subsequent internalization into the tumor cell, the decay of Lead-212 releases high-energy alpha radiation. These alpha particles cause lethal double-strand DNA breaks within a very short range, effectively killing the target cancer cells while sparing surrounding healthy tissue. 212Pb-LNC1011M is currently in preclinical development.
- Other names
- LNC1011 (212Pb conjugate)
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 212Pb-LNC1011M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 212Pb-LNC1011M.